Investor Alert (NYSE
AGL): Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against agilon health, inc. With Expanded Class Period and Encourages Investors With Substantial Losses to Contact the Firm
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against agilon health, inc. (NYSE: AGL) (“agilon” or the “Company”) on behalf of investors who purchased or acquired agilon common stock between November 4, 2022, and January 4, 2024, inclusive (the “Class Period”). This action, captioned Hope v. agilon health, inc., et al., Case No. 1:24-cv-00305, is filed in the United States District Court for the Western District Texas.
Important Deadline Reminder: There is one related class action case pending against agilon in the United States District Court for the Western District of Texas. That first-filed action issued a notice of its filing pursuant to the federal securities laws which triggered the deadline of May 20, 2024, for any investors who purchased agilon common stock to seek to be appointed as a lead plaintiff representative of the class. The filing of the Hope Action does not change the May 20, 2024, lead plaintiff deadline.
CLICK HERE TO SUBMIT YOUR AGILON LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/agilon-health-inc?utm_source=PR&utm ...
LEAD PLAINTIFF DEADLINE: MAY 20, 2024
CLASS PERIOD: NOVEMBER 4, 2022, THROUGH JANUARY 4, 2024
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. (484) 270-1453 or Email at info@ktmc.com
DEFENDANTS’ MISCONDUCT
agilon is a healthcare and technology company that acts as an intermediary between physician groups that provide medical services to senior citizens and Medicare
and Medicare Advantage insurers. One of agilon’s key financial metrics is “medical margin,” which the Company defines as medical services revenue less medical services expenses.
Lesen Sie auch
The Class Period begins on November 4, 2022, when agilon announced its financial results for the third quarter of 2022 (filed after the market closed the prior evening). In connection with these results, Defendant Sell (agilon’s CEO) emphasized the Company’s “[m]embership, revenue and medical margins were above the high end of our guidance ranges” and indicated that, “[t]his year, we are driving substantial growth in medical margin PMPM [per member per month].” Defendant Bensley (agilon’s CFO) stated that, “[f]or the full year 2022, we have raised our membership, revenue and medical margin outlook to reflect the strong performance in our [Medicare Advantage] business.”